Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for pulmonary tumor thrombotic microangiopathy
jRCTs031210348Completed
- Sponsor
- University of Tsukuba Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ponatinib in Pulmonary tumor thrombotic microangiopathy (PTTM), sponsored by University of Tsukuba Hospital. Primary endpoints: Composite primary outcome of all-cause death and severe vascular occlusive event and Prevalence of ponatinib-related adverse events grade ≥2. Started Mar 2022; status: completed.
02
Drugs
ponatinib
03
Conditions
Pulmonary tumor thrombotic microangiopathy (PTTM)
Beyond the preview
Go deeper on jRCTs031210348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210348.